Cargando...
RTOG 0913: A Phase I Study of Daily Everolimus (RAD001) In Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma
PURPOSE: To determine the safety of the mTOR inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients. METHODS AND MATERIALS: Everolimus was administered daily with concurrent radiation (60 Gy in 30 fractions) and temozolomi...
Gardado en:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3766839/ https://ncbi.nlm.nih.gov/pubmed/23725999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2013.04.036 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|